TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05899920

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Blood samples will be taken for pharmacokinetics and pharmacogenetics
Description: To assess antihypertensive drugs concentration (lisinopril, valsartan, amlodipine, indapamide

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Blood samples will be taken for pharmacokinetics and pharmacogenetics
Description: To assess antihypertensive drugs concentration (lisinopril, valsartan, amlodipine, indapamide
Study: NCT05945992

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Emotion regulation
Description: Psycho-education elements concerning the emergence and functions of emotions, progressive muscle relaxation (PMR), analysis of emotional situations and group exercises
Study: NCT04939116

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ANG-3070
Description: Orally administered tyrosine kinase inhibitor capsule

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Orally administered placebo capsule
Study: NCT06556342

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FRD001
Description: FRD001 injection is a lipid-based second-generation ultrasound contrast agent. FRD001 injection in ultrasound contrast imaging could enhance the differentiation between benign and malignant ovarian masses in women, using gray-scale and power Doppler ultrasound as controls.
Study: NCT05806411

Intervention type: DIAGNOSTIC_TEST
Intervention: Analysis of calcific aortic valves
Description: Microbiologic analysis of calcofic aortic valves

Intervention type: DIAGNOSTIC_TEST
Intervention: Analysis of calcific aortic valves
Description: Microbiologic analysis of calcofic aortic valves
Study: NCT05248867

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo solution for injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AGN-151586
Description: AGN-151586 solution for injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: AGN-151586
Description: AGN-151586 solution for injection
Study: NCT05995483

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Early Diagnosis on BSE
Description: the System Which Sends Reminder Notifications Directing Them to the Website Containing BSE Training Along With the Illustrations Created for the Practice Prepared by the Researcher on the Determined Ideal Day.
Study: NCT05005793

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium bicarbonate
Description: Oral sodium bicarbonate at 0.5 mEq/kg-lean body weight/day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo at 0.5 mEq/kg-lean body weight/day
Study: NCT06556732

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Eplereone
Description: Group A (study group): 50 patients received eplerenon 25 mg daily plus amiodarone and other medications not including non-dihydropyridine calcium channel blocker or digoxin.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eplereone
Description: Group A (study group): 50 patients received eplerenon 25 mg daily plus amiodarone and other medications not including non-dihydropyridine calcium channel blocker or digoxin.
Study: NCT06409923

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Stimulation of mandibular growth.
Description: orthodontic treatment where a retrognathic mandibula is put into an anterior position to stimulate mandibular growth. This will happen by either the MA-invisalign system or the herbst appliance

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Stimulation of mandibular growth.
Description: orthodontic treatment where a retrognathic mandibula is put into an anterior position to stimulate mandibular growth. This will happen by either the MA-invisalign system or the herbst appliance
Study: NCT05593146

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: modified anteversion angle placement(( α-15°)±10°)
Description: Preoperative examination was conducted to determine a safe surgical margin in all patients. A 3D printed osteotomy guide combined with a 3D printed prosthesis pre- designed anteversion angle is assembled for reconstruction after tumor resection.~Once completed, intraoperative X-ray fluoroscopy was applied to evaluate the anteversion angle of the acetabular component. If the anteversion angle doesn't meet the predetermined criteria, it needs to be adjusted until it does.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: conventional anteversion angle placement ( α±10°)
Description: Preoperative examination was conducted to determine a safe surgical margin in all patients. A 3D printed osteotomy guide combined with a 3D printed prosthesis with predesigned anteversion angle is assembled for reconstruction following tumor resection.~Once completed, intraoperative X-ray fluoroscopy was applied to evaluate the anteversion angle of the acetabular component. If the anteversion angle doesn't meet the predetermined criteria, it needs to be adjusted until it does.
Study: NCT05097781

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD-1 blocking antibody
Description: All patients with more than one distant metastatic lesions will accept at least one site of radiotherapy and PD-1 blockade at the same time.
Study: NCT05945992

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Emotion regulation
Description: Psycho-education elements concerning the emergence and functions of emotions, progressive muscle relaxation (PMR), analysis of emotional situations and group exercises

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Emotion regulation
Description: Psycho-education elements concerning the emergence and functions of emotions, progressive muscle relaxation (PMR), analysis of emotional situations and group exercises

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Emotion regulation
Description: Psycho-education elements concerning the emergence and functions of emotions, progressive muscle relaxation (PMR), analysis of emotional situations and group exercises

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Emotion regulation
Description: Psycho-education elements concerning the emergence and functions of emotions, progressive muscle relaxation (PMR), analysis of emotional situations and group exercises

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Emotion regulation
Description: Psycho-education elements concerning the emergence and functions of emotions, progressive muscle relaxation (PMR), analysis of emotional situations and group exercises

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Emotion regulation
Description: Psycho-education elements concerning the emergence and functions of emotions, progressive muscle relaxation (PMR), analysis of emotional situations and group exercises

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Emotion regulation
Description: Psycho-education elements concerning the emergence and functions of emotions, progressive muscle relaxation (PMR), analysis of emotional situations and group exercises

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-acceptance
Description: Exercises and guided self-experience targeting heightened knowledge about oneself and acceptance of all personal strengths and weaknesses, exercises based on the internal family systems by R. Schwartz.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-acceptance
Description: Exercises and guided self-experience targeting heightened knowledge about oneself and acceptance of all personal strengths and weaknesses, exercises based on the internal family systems by R. Schwartz.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-acceptance
Description: Exercises and guided self-experience targeting heightened knowledge about oneself and acceptance of all personal strengths and weaknesses, exercises based on the internal family systems by R. Schwartz.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-acceptance
Description: Exercises and guided self-experience targeting heightened knowledge about oneself and acceptance of all personal strengths and weaknesses, exercises based on the internal family systems by R. Schwartz.
Study: NCT04899102

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Time-Restricted, Intermittent Fasting
Description: A special type of diet for 6 weeks, called time-restricted, intermittent fasting.
Study: NCT05610683

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hemodialysis sessions using SHFVE dialyzer (VieX™) or the MCO (Theranova 500™) dialyzer
Description: Patients will receive thrice weekly 4 hours hemodialysis sessions during 3 months

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hemodialysis sessions using SHFVE dialyzer (VieX™) or the MCO (Theranova 500™) dialyzer
Description: Patients will receive thrice weekly 4 hours hemodialysis sessions during 3 months
Study: NCT05984095

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telerehabilitation
Description: The intervention was administered in a telerehabilitation fashion through a videocall on the phone or tablet, by a physiotherapist, in a one-to-one session.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Telerehabilitation
Description: The intervention was administered in a telerehabilitation fashion through a videocall on the phone or tablet, by a physiotherapist, in a one-to-one session.
Study: NCT06304428

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Deprescribing Care Model
Description: The Deprescribing Care Model is designed to deprescribe fall related medications (FRIDs)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Bone Health Service Model
Description: The Bone Health Service Model is designed to provide osteoporosis evaluation and management

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Injury Prevention Service Model
Description: The Injury Prevention Service Model provides both the Deprescribing Care Model and the Bone Health Service Model.
Study: NCT06290830

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Abdominal massage group
Description: abdominal massage creates reflex and mechanical movement of the intestines by applying pressure to the rectum and changing intra-abdominal pressure.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Kegel Exercises group
Description: Kegel exercises (also called pelvic floor exercises) have a functional connection with other core muscles and contribute to the synergistic effect of the abdominal and pelvic floor muscles

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Both abdominal massage and kegel exercises to gether
Description: with both exercises are performed to accelerate the peristalsis movement by mechanical movements
Study: NCT06346288

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Breast Milk Sampling
Description: Pharmacokinetic (PK) samples will be taken from breast milk of lactating mothers on an established dosing regimen of commercial risankizumab at pre-dose and 1 hour after dosing on Day 1, on Days 4 (± 1), 8 (± 2), 15 (± 3), 29 (± 3), and pre-dose on Day 57 (± 3)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Risankizumab
Description: Participants will have already been taking commercial risankizumab and will continue on commercial risankizumab. Participants will not be provided risankizumab from the study. Participants must have received at least 2 doses of 360 mg of risankizumab SC every 8 weeks postpartum prior to start of participation in this study.
Study: NCT05392127

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR0302 Tablets
Description: SHR0302 Tablets once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam Maleate Tablets
Description: Midazolam Maleate Tablets single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Warfarin Sodium Tablets
Description: Warfarin Sodium Tablets single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omeprazole Enteric Capsules
Description: Omeprazole Enteric Capsules single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin K1 Tablets
Description: Vitamin K1 Tablets once daily
Study: NCT05945992

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-acceptance
Description: Exercises and guided self-experience targeting heightened knowledge about oneself and acceptance of all personal strengths and weaknesses, exercises based on the internal family systems by R. Schwartz.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-acceptance
Description: Exercises and guided self-experience targeting heightened knowledge about oneself and acceptance of all personal strengths and weaknesses, exercises based on the internal family systems by R. Schwartz.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-acceptance
Description: Exercises and guided self-experience targeting heightened knowledge about oneself and acceptance of all personal strengths and weaknesses, exercises based on the internal family systems by R. Schwartz.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-acceptance
Description: Exercises and guided self-experience targeting heightened knowledge about oneself and acceptance of all personal strengths and weaknesses, exercises based on the internal family systems by R. Schwartz.
Study: NCT05392127

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Repaglinide Tablets
Description: Repaglinide Tablets single dose
Study: NCT05796453

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Clareon Vivity IOL - Non Toric
Description: Spherical extended vision IOL implanted in the capsular bag of the eye for the visual correction of aphakia in adult patients with less than 1.00 diopter of preoperative corneal astigmatism in whom a cataractous lens has been removed.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Clareon Vivity IOL - Toric
Description: Toric extended vision IOL implanted in the capsular bag of the eye for the visual correction of aphakia and for reduction of residual refractive astigmatism in adult patients in whom a cataractous lens has been removed.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Clareon PanOptix Trifocal IOL - Non Toric
Description: Spherical trifocal IOL implanted in the capsular bag of the eye for the visual correction of aphakia in adult patients with less than 1.00 diopter of preoperative corneal astigmatism in whom a cataractous lens has been removed.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Clareon PanOptix Trifocal IOL - Toric
Description: Toric trifocal IOL implanted in the capsular bag of the eye for the visual correction of aphakia and for reduction of residual refractive astigmatism in adult patients in whom a cataractous lens has been removed.
Study: NCT05945992

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness
Description: Guided mindfulness-exercises, different meditation techniques like body scan, breathing meditation. Reflection and exchange within the group

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness
Description: Guided mindfulness-exercises, different meditation techniques like body scan, breathing meditation. Reflection and exchange within the group
Study: NCT04459468

Intervention type: DRUG
Intervention: Lipiodol
Description: Lipiodol TACE procedure
Study: NCT05147142

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Low Intensity Focused Ultrasound
Description: Brainsonix BX Pulsar 1002

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Low Intensity Focused Ultrasound
Description: Brainsonix BX Pulsar 1002
Study: NCT06592703

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adipose tissue-derived Mesenchymal Stromal Cells
Description: repeated allogenic ASCs IT injections
Study: NCT06589154

Intervention type: DIAGNOSTIC_TEST
Intervention: Prostatic or Pelvic MR
Description: Participants are required to undergo prostatic or pelvic MR according to the investigators.

Intervention type: DIAGNOSTIC_TEST
Intervention: Prostatic Biopsy
Description: Participants are required to undergo prostatic biopsy according to the clinical indication and investigators.
Study: NCT06660667

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SAR402663
Description: Pharmaceutical form:Liquid formulation-Route of administration:Intravitreal injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SAR402663
Description: Pharmaceutical form:Liquid formulation-Route of administration:Intravitreal injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SAR402663
Description: Pharmaceutical form:Liquid formulation-Route of administration:Intravitreal injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diluent
Description: Pharmaceutical form:Liquid solution-Route of administration:Intravitreal injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diluent
Description: Pharmaceutical form:Liquid solution-Route of administration:Intravitreal injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diluent
Description: Pharmaceutical form:Liquid solution-Route of administration:Intravitreal injection
Study: NCT06663072

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: Safety-Run In: Starting Dose: 500 mg IM on Days 1, 15, and 29 of Cycle 1; followed by 500 mg IM on Days 1 and 29 of every cycle thereafter for a total of 9 doses.~Dose Expansion: 500 mg IM: Days 1, 15, and 29 of Cycle 1; followed by 500 mg IM on Days 1 and 29 of every cycle thereafter for a total of 9 doses.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: Safety-Run In: Starting Dose: 500 mg IM on Days 1, 15, and 29 of Cycle 1; followed by 500 mg IM on Days 1 and 29 of every cycle thereafter for a total of 9 doses.~Dose Expansion: 500 mg IM: Days 1, 15, and 29 of Cycle 1; followed by 500 mg IM on Days 1 and 29 of every cycle thereafter for a total of 9 doses.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 177Lu-DOTATATE
Description: Safety-Run In: Starting Dose: 7.4 GBq (200 mCi) IV every 8 weeks for a total of 4 Cycles~Dose Expansion:177Lu-DOTATATE7.4 GBq (200 mCi) IV or 3.7 GBq (100 mCi) IV: IV dose every 8 weeks for a total of 4 Cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 177Lu-DOTATATE
Description: Safety-Run In: Starting Dose: 7.4 GBq (200 mCi) IV every 8 weeks for a total of 4 Cycles~Dose Expansion:177Lu-DOTATATE7.4 GBq (200 mCi) IV or 3.7 GBq (100 mCi) IV: IV dose every 8 weeks for a total of 4 Cycles.
Study: NCT05106036

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Clinical Support Decision Tool
Description: Participants whose home blood pressure reading average is systolic ≥ 130 and diastolic ≥ 80 will trigger the Clinical Decision Support (CDS) tool to assist their physicians with their blood pressure management. Home BP data will be averaged each month via Omron Connect app on the patients' smartphone, which is programmed to send home BP readings to MyChart via Apple or Google Health. We have designed CDS to present treatment choices of antihypertensive medication regimen based on medications patients are currently taking. For example, patients who are currently taking an angiotensin converting enzyme inhibitor (ACEI) or angiotensin receptor blocker (ARB), our CDS algorithm will recommend addition of a calcium channel blocker as the first tier of recommendation and thiazide diuretics as second tier of recommendation. Laboratory data and home BP in the past month will be presented in a clear and simple manner for the clinicians to activate and use to optimize BP control.
Study: NCT06592768

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Briquilimab
Description: Subcutaneous Administration

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator
Description: Subcutaneous Administration
Study: NCT05757193

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: DeltaG (250 mg/kg)
Description: 250 mg/kg of (R)-3-hydroxybutyl (R)-3-hydroxybutyrate

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: DeltaG (500 mg/kg)
Description: 500 mg/kg of (R)-3-hydroxybutyl (R)-3-hydroxybutyrate
Study: NCT06609330

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Countering Chronic Anger and Aggression Related to Trauma and Transgressions (CART)
Description: Countering Chronic Anger and Aggression Related to Trauma and Transgressions (CART), a novel intervention for reducing chronic anger and aggression and improving interpersonal relationships, in military personnel who have experienced military-related betrayal delivered in 14 treatment modules twice a week.
Study: NCT06417450

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Non-invasive Neuromodulation
Description: Patients receive non-invasive neurostimulation through the Nesa device

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Non-invasive Neuromodulation
Description: The same protocol described for the experimental group will be applied, but electrical stimulation device which will be previously manipulated and tested with an oscilloscope so that they do not emit electrical currents.
Study: NCT04954040

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine Pill + Azithromycin Pill
Description: Hydroxychloroquine. 1st day 200mg 2-0-2; 2nd to 5th day 200mg 1-0-1 Azithromycin.~1st day 500m 0-1-0, 2nd to 5th day 250mg 0-1-0

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SOC
Description: Acetaminophen or Metamizole. Antitussives if needed.
Study: NCT05744206

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electrocardiogram measurements by holter device and patch-type electrocardiographic at the same time
Description: The patient is measured electrocardiogram simultaneously through a holter device and patch-type electrocardiograph
Study: NCT05945992

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Control component 1_social behaviors in groups
Description: Control component for emotion regulation

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control component 1_social behaviors in groups
Description: Control component for emotion regulation

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Control component 1_social behaviors in groups
Description: Control component for emotion regulation
Study: NCT05226819

Intervention type: DRUG
Group type: OTHER
Intervention: PPI quadruple therapy
Description: Among these outpatients, H. pylori-negative patients don't give any intervention. But H. pylori-positive patients are given rabeprazole 10mg + amoxicillin 1000mg + clarithromycin 500mg + colloidal bismuth tartrate 220mg bid for 14 days. After 4-6 weeks of completing eradication therapy, 13C-UBT is performed.

Intervention type: DRUG
Group type: OTHER
Intervention: PPI quadruple therapy
Description: Among these outpatients, H. pylori-negative patients don't give any intervention. But H. pylori-positive patients are given rabeprazole 10mg + amoxicillin 1000mg + clarithromycin 500mg + colloidal bismuth tartrate 220mg bid for 14 days. After 4-6 weeks of completing eradication therapy, 13C-UBT is performed.